BofA downgraded Turnstone Biologics (TSBX) to Underperform from Neutral with a 40c price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSBX:
- Turnstone Biologics Faces Financial and Operational Challenges
- Turnstone Biologics reports Q3 EPS (74c), consensus (86c)
- TSBX Earnings this Week: How Will it Perform?
- Turnstone Biologics presents two posters on methods for TIL selection at SITC
- Turnstone Biologics downgraded to Neutral at BofA after restructuring